Oncology Exchange

PUBLIC PROFILE

FDA Approves First KRAS-Targeted Therapy, Lumakras, for NSCLC

Posted by Charles Decuir on June 7, 2021 3:30 PM EDT
Charles Decuir photo

The FDA granted accelerated approval to the RAS GTPase inhibitor sotorasib (Lumakras, Amgen) for the treatment of adults with KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. 

This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for approximately 25% of mutations in NSCLC. KRAS G12C mutations represent approximately 13% of mutations in NSCLC.

The agency also approved the QIAGEN Therascreen KRAS RGQ PCR kit (tissue) and the Guardant360 CDx (plasma) as companion diagnostics for use with sotorasib. If no mutation is detected in a plasma specimen, the tumor tissue should be tested.

https://www.clinicaloncology.com/FDA-Watch/Article/06-21/FDA-Approves-First-KRAS-Targeted-Therapy-Lumakras-for-NSCLC/63758

There are no comments

Sign in to add your comment.

Recent Posts

Immunotherapy Drug Keytruda Approved For Colon Cancer Patients With Specific Tumor Abnormalities
A new option for the treatment of metastatic colorectal cancer, immune checkpoint inhibitor...
read more
Novel Therapy Shows Promise in Group of Patients with Metastatic Colon Cancer
Patients with HER2-expressing metastatic colorectal cancer appeared to achieve durable and promising...
read more
Provectus Biopharmaceuticals Announces Publication of In Vitro Data from Research on Oral Delivery of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
KNOXVILLE, TN, June 09, 2021 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that...
read more
Advarra expands Gene Therapy Ready network with 500+ sites
June 9, 2021 -- Advarra's Gene Therapy Ready network has grown to over 500 registered research...
read more
Old antidepressants show promise as immuno-oncology treatments in melanoma and colon cancer
A class of antidepressants known as monoamine oxidase inhibitors (MAOIs) first hit the market in the...
read more
Newly identified protein could become target for cancer immunotherapy
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to...
read more
Investors buoyed by positive data for Immutep’s immunotherapy
Small cap immunotherapy biotech Immutep is a step closer to commercialising its leading drug...
read more
FDA Approves First KRAS-Targeted Therapy, Lumakras, for NSCLC
The FDA granted accelerated approval to the RAS GTPase inhibitor sotorasib (Lumakras, Amgen) for the...
read more
American Oncology Network Physicians Research to be Well Represented at the ASCO21 Virtual Scientific Program
Fort Myers, Fla., June 07, 2021 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) is pleased...
read more
Researchers to develop new technology to detect and remove cancer tumors
New technology that will marry probes that can detect cancer tumors through the skin with...
read more

Go to blog